Search research articles
Contact Us
Filters
Showing results (311-320 of 523) with videos related to
Page
of 53
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV
|
October 4, 2016
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies
A B Gottlieb, J-P Lacour, N Korman, et al.
Journal of Cutaneous Pathology
|
February 1, 1991
Fixed drug eruptions: evidence for a cytokine-mediated process
B R Smoller, A D Luster, J F Krane, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 6, 2005
TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques
Alice B Gottlieb, Francesca Chamian, Salman Masud, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
October 7, 2014
Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption
K B Gordon, A B Gottlieb, R G Langely, et al.
Dermatology and Therapy
|
March 8, 2026
Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality
Manuelle Viguier, Denis Jullien, Laurent Misery, et al.
Annals of the Rheumatic Diseases
|
April 22, 2016
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
Arthur Kavanaugh, Lluis Puig, Alice B Gottlieb, et al.
The British Journal of Dermatology
|
March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3
K A Papp, K B Gordon, R G Langley, et al.
Human Molecular Genetics
|
January 1, 1994
Complete androgen insensitivity due to mutations in the probable alpha-helical segments of the DNA-binding domain in the human androgen receptor
L K Beitel, L Prior, D M Vasiliou, et al.
Journal of Drugs in Dermatology : JDD
|
August 16, 2017
International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working Group
Lourdes M Perez-Chada, Sanminder Singh, Kristina Callis-Duffin, et al.
Clinical Immunology (Orlando, Fla.)
|
April 20, 2004
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
Alice B Gottlieb, Sewon Kang, Kenneth G Linden, et al.
Page
of 53
Search research articles
Search
Showing results (311-320 of 523) with videos related to
Sort By:
Page
of 53
Journal of the European Academy of Dermatology and Venereology : JEADV
|
October 4, 2016
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies
A B Gottlieb, J-P Lacour, N Korman, et al.
Journal of Cutaneous Pathology
|
February 1, 1991
Fixed drug eruptions: evidence for a cytokine-mediated process
B R Smoller, A D Luster, J F Krane, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 6, 2005
TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques
Alice B Gottlieb, Francesca Chamian, Salman Masud, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
October 7, 2014
Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption
K B Gordon, A B Gottlieb, R G Langely, et al.
Dermatology and Therapy
|
March 8, 2026
Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality
Manuelle Viguier, Denis Jullien, Laurent Misery, et al.
Annals of the Rheumatic Diseases
|
April 22, 2016
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
Arthur Kavanaugh, Lluis Puig, Alice B Gottlieb, et al.
The British Journal of Dermatology
|
March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3
K A Papp, K B Gordon, R G Langley, et al.
Human Molecular Genetics
|
January 1, 1994
Complete androgen insensitivity due to mutations in the probable alpha-helical segments of the DNA-binding domain in the human androgen receptor
L K Beitel, L Prior, D M Vasiliou, et al.
Journal of Drugs in Dermatology : JDD
|
August 16, 2017
International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working Group
Lourdes M Perez-Chada, Sanminder Singh, Kristina Callis-Duffin, et al.
Clinical Immunology (Orlando, Fla.)
|
April 20, 2004
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
Alice B Gottlieb, Sewon Kang, Kenneth G Linden, et al.
Page
of 53